Citadel Advisors’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,700
| Closed | -$371K | – | 12916 |
|
|
2025
Q4 | $371K | Sell |
4,700
-1,200
| -20% | -$104K | ﹤0.01% | 9695 |
|
|
2025
Q3 | $540K | Buy |
+5,900
| New | +$481K | ﹤0.01% | 8947 |
|
|
2025
Q2 | – | Sell |
-2,000
| Closed | -$134K | – | 12410 |
|
|
2025
Q1 | $134K | Sell |
2,000
-1,400
| -41% | -$83.6K | ﹤0.01% | 11042 |
|
|
2024
Q4 | $188K | Sell |
3,400
-8,300
| -71% | -$477K | ﹤0.01% | 10554 |
|
|
2024
Q3 | $698K | Sell |
11,700
-700
| -6% | -$42.7K | ﹤0.01% | 7550 |
|
|
2024
Q2 | $790K | Buy |
12,400
+1,700
| +16% | +$110K | ﹤0.01% | 7070 |
|
|
2024
Q1 | $740K | Sell |
10,700
-2,100
| -16% | -$127K | ﹤0.01% | 7547 |
|
|
2023
Q4 | $706K | Buy |
12,800
+2,600
| +25% | +$143K | ﹤0.01% | 7379 |
|
|
2023
Q3 | $592K | Buy |
10,200
+800
| +9% | +$46.2K | ﹤0.01% | 7691 |
|
|
2023
Q2 | $506K | Buy |
9,400
+1,000
| +12% | +$44.3K | ﹤0.01% | 7916 |
|
|
2023
Q1 | $334K | Buy |
8,400
+5,700
| +211% | +$240K | ﹤0.01% | 9163 |
|
|
2022
Q4 | $109K | Buy |
+2,700
| New | +$101K | ﹤0.01% | 11104 |
|
|
2022
Q1 | – | Sell |
-8,900
| Closed | -$410K | – | 13499 |
|
|
2021
Q4 | $410K | Buy |
8,900
+1,400
| +19% | +$60.2K | ﹤0.01% | 10151 |
|
|
2021
Q3 | $246K | Buy |
+7,500
| New | +$233K | ﹤0.01% | 11511 |
|
|
2020
Q2 | – | Sell |
-10,600
| Closed | -$432K | – | 9720 |
|
|
2020
Q1 | $432K | Buy |
10,600
+2,800
| +36% | +$149K | ﹤0.01% | 6709 |
|
|
2019
Q4 | $481K | Buy |
7,800
+100
| +1% | +$6.62K | ﹤0.01% | 6865 |
|
|
2019
Q3 | $561K | Sell |
7,700
-1,700
| -18% | -$127K | ﹤0.01% | 6554 |
|
|
2019
Q2 | $773K | Sell |
9,400
-3,100
| -25% | -$220K | ﹤0.01% | 6117 |
|
|
2019
Q1 | $882K | Buy |
12,500
+2,900
| +30% | +$171K | ﹤0.01% | 5811 |
|
|
2018
Q4 | $432K | Sell |
9,600
-6,700
| -41% | -$351K | ﹤0.01% | 6631 |
|
|
2018
Q3 | $922K | Buy |
16,300
+7,500
| +85% | +$459K | ﹤0.01% | 5691 |
|
|
2018
Q2 | $588K | Buy |
8,800
+5,300
| +151% | +$331K | ﹤0.01% | 6107 |
|
|
2018
Q1 | $204K | Buy |
+3,500
| New | +$222K | ﹤0.01% | 7320 |
|
|
2017
Q4 | – | Sell |
-6,100
| Closed | -$320K | – | 7924 |
|
|
2017
Q3 | $320K | Buy |
+6,100
| New | +$291K | ﹤0.01% | 5969 |
|
|
2017
Q2 | – | Sell |
-4,200
| Closed | -$208K | – | 7428 |
|
|
2017
Q1 | $208K | Sell |
4,200
-13,100
| -76% | -$736K | ﹤0.01% | 6449 |
|
|
2016
Q4 | $1.05M | Sell |
17,300
-16,500
| -49% | -$1.01M | ﹤0.01% | 3794 |
|
|
2016
Q3 | $2.24M | Sell |
33,800
-8,800
| -21% | -$550K | ﹤0.01% | 2828 |
|
|
2016
Q2 | $2.38M | Buy |
42,600
+20,100
| +89% | +$977K | ﹤0.01% | 2555 |
|
|
2016
Q1 | $757K | Sell |
22,500
-300
| -1% | -$10.2K | ﹤0.01% | 3825 |
|
|
2015
Q4 | $1.03M | Buy |
22,800
+11,200
| +97% | +$482K | ﹤0.01% | 3526 |
|
|
2015
Q3 | $458K | Sell |
11,600
-3,500
| -23% | -$199K | ﹤0.01% | 4925 |
|
|
2015
Q2 | $937K | Buy |
15,100
+5,300
| +54% | +$315K | ﹤0.01% | 4040 |
|
|
2015
Q1 | $613K | Buy |
9,800
+9,700
| +9,700% | +$590K | ﹤0.01% | 4614 |
|
|
2014
Q4 | $6K | Buy |
+100
| New | +$4.41K | ﹤0.01% | 8233 |
|
Other funds holding ANIP
VCM
SCM
TCM
GAM
DTC
Citadel Advisors's ANIP Position: Q1 2026 in Review
Citadel Advisors increased its ANI Pharmaceuticals (ANIP) stake by 464% in Q1 2026, buying an estimated $7.39M and bringing the position to 115,082 shares worth $8.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.
Citadel Advisors first reported a position in ANIP in Q2 2013 and has held it in 43 quarters since. The position peaked at $53.1M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.
- Citadel Advisors held 115,082 shares of ANI Pharmaceuticals worth $8.85M as of Q1 2026.
- Citadel Advisors bought 94,667 ANI Pharmaceuticals shares in Q1 2026, an estimated $7.39M.
- ANI Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3426 holding.
- Citadel Advisors first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Citadel Advisors's ANI Pharmaceuticals position peaked at $53.1M in Q3 2025.
- 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.